Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Clinical efficacy and safety of daratumumab-carfilzomib based therapy in newly diagnosed multiple myeloma: A retrospective cohort analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

MXMan XuKQKun Qian

Discussion

Loading...

Member takes

Overview

Retrospective analysis showed daratumumab and carfilzomib improved responses in newly diagnosed myeloma patients, indicating effective treatment options.

Key Points

  • To evaluate the efficacy and safety of daratumumab-carfilzomib based therapy in patients with newly diagnosed multiple myeloma not undergoing ASCT.
  • Retrospective cohort study at a single center
  • 21 adults with newly diagnosed multiple myeloma
  • Administered DK-based regimens over 28-day cycles
  • Measured overall response rate (ORR), progression-free survival (PFS), and adverse events.
  • Overall response rate (ORR) was 90.5% with 47.6% achieving complete response (CR)
  • Median follow-up of 12.3 months showed promising PFS rates of 87%
  • Hematologic toxicities were most common with 19% grade ≥3 anemia.

Cite This Study

Xu et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e08ehttps://doi.org/10.1182/blood-2025-7579
View Full Paper
Ask AI
Bookmark
Share